On Sep 28, 2023: FabreKramer Pharmaceuticals Announcesd the FDA Approval of EXXUA™, the Oral Selective 5HT1a Receptor Agonist for the Treatment of Major Depressive Disorder in Adults.

Psychiatry Education Forum Academy has summarized this newly approved medication in clinically relevant discussions:
1. Indication
2. Mechanism of Action
3. Lab work needed before initiating the medication
4. How to Dose?
5. When to use the low dose?
6. Drug Interactions to consider?
7. Contraindications
8. Common side effects
9. Pregnancy risk?

Read the detaield post here: https://psychiatryeducationforum.com/...